Skip to content
value.today

General Oncology, Inc.

🇺🇸 Newton, Massachusetts, USABiotechnologyFounded 2015
Total raised
$16 M
2 rounds on record
Latest round
$5 M
Apr 2026
First round on record
Jun 2019
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of General Oncology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2026$5 MNo. 2$2 to $10 million

General Oncology, Inc.: Raise no. 2, Apr 2026

Investors in this round

37 investors had bought by the notice of Apr 23, 2026: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, other: Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may conve
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abid Aaron Ansari · Executive Officer
  • Arnold Aaron Glazier · Executive Officer, Director
  • Jeffrey Aaron Glazier · Executive Officer, Director
  • Barry J. Seeman · Director
  • Michael J. Petit · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees or to related entities to those listed in Item 3.”

Signed by Jeffrey Aaron Glazier, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 23, 2026. Read the notice at the SEC.

optionsSEC
Jun 2019$11 MNo. 1$10 to $50 million

General Oncology, Inc.: Raise no. 1, Jun 2019

Investors in this round

43 investors had bought by the notice of Jul 2, 2025: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $17 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abid J. Ansari · Executive Officer
  • Arnold Aaron Glazier · Executive Officer, Director
  • Jeffrey Aaron Glazier · Executive Officer, Director
  • Barry J. Seeman · Director
  • Michael J. Petit · Director
  • Michael J. Petit · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Aaron Glazier, President. Source: SEC Form D and 6 amendments, newest notice filed Jul 2, 2025. Read the notice at the SEC.

equity, optionsSEC
Nov 2015$35 MIssued in a merger or acquisition$10 to $50 million

General Oncology, Inc.: Private sale, Nov 2015

Investors in this round

140 investors had bought by the notice of Sep 5, 2017: 140 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $47 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arnold Glazier · Executive Officer, Director
  • Gregg Goldstein · Executive Officer, Director
  • Henry Esber · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “A portion of the securities being offered is in connection with certain business combination transactions.”

Signed by Gregg Goldstein, President. Source: SEC Form D and 1 amendment, newest notice filed Sep 5, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • General Oncology, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2026).

    SEC Form D · Apr 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2026

That is all the official record says: General Oncology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of General Oncology, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 43 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by General Oncology, Inc.
NameRoleNamed in
Abid Aaron AnsariExecutive officerApr 2026
Arnold Aaron GlazierExecutive officerApr 2026
Jeffrey Aaron GlazierExecutive officerApr 2026
Abid J. AnsariExecutive officerJul 2025
Arnold GlazierExecutive officerJul 2024
Gregg GoldsteinExecutive officerJul 2024
Arnold Aaron GlazierDirectorApr 2026
Barry J. SeemanDirectorApr 2026
Jeffrey Aaron GlazierDirectorApr 2026
Michael J. PetitDirectorApr 2026
Arnold GlazierDirectorJul 2024
Gregg GoldsteinDirectorJul 2024
Michael D. SigmanDirectorJul 2024
Henry EsberDirectorSep 2017